Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study

Su Jin Lee1,2, Kyoung Hwa Ha3,4, Jung Hyun Lee5, Hokyou Lee2, Dae Jung Kim3,4, Hyeon Chang Kim2,5*

1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, 2 Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea, 3 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea, 4 Cardiovascular and Metabolic Disease Etiology Research Center, Ajou University School of Medicine, Suwon, Korea, 5 Cardiovascular and Metabolic Disease Etiology Research Center, Yonsei University College of Medicine, Seoul, Korea

* hckim@yuhs.ac

Abstract

Aim
To compare the risks of hospitalization for heart failure (HHF) associated with sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP-4i), and thiazolidinedione (TZD) as add-on medications to metformin (MET) therapy using the data of Korean adults with type-2 diabetes from the Korean National Health Insurance database.

Methods
We identified 98,383 people who received SU (n = 42,683), DPP-4i (n = 50,310), or TZD (n = 5,390) added to initial treatment of MET monotherapy in patients with type-2 diabetes. The main outcome was the hospitalization for HHF. Hazard ratios for HHF by type of second-line glucose-lowering medication were estimated by Cox-proportional hazard models. Sex, age, duration of MET monotherapy, Charlson Comorbidity Index and additional comorbidities, and calendar year were controlled as potential confounders.

Results
The observed numbers (rate per 100,000 person-years) of HHF events were 1,129 (658) for MET+SU users, 710 (455) for MET+DPP-4i users, and 110 (570) for MET+TZD users. Compared to that for MET+SU users (reference group), the adjusted hazard ratios for HHF events were 0.76 (95% confidence interval 0.69–0.84) for MET+DPP-4i users and 0.96 (95% confidence interval 0.79–1.17) for MET+TZD users.

Conclusion
DPP-4i as an add-on therapy to MET may lower the risks of HHF compared with SU.
Introduction

Heart failure (HF) is one of the main health burdens of cardiovascular disease (CVD) in people with type-2 diabetes mellitus (T2D) [1]. Pathogenic elements central to HF in T2D are hypertension, atherosclerotic vascular disease, and diabetic cardiomyopathy related to insulin resistance. Although HF may be one of several fatal complications of T2D, HF could be preventable or treatable with drugs [2]. Thus, identifying the appropriate drug for glycemic control is important in the treatment of T2D to prevent HF.

Metformin (MET) is the most commonly used starting drug for patients with T2D on the basis of international guidelines [3]. In Korea, MET is the preferred initial oral antidiabetic drug, and it has also been the most commonly prescribed antidiabetic medication since 2010 [4, 5]. In addition, in 2016, >80% of dual therapy regimens included MET as the first-line therapy. As second-line therapies added to MET, sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP-4i), and thiazolidinedione (TZD) have been most frequently prescribed in Korea according to data from the Korean Diabetes Association [4]. MET+SU was the most common dual therapy protocol until 2014. However, at present, MET+DPP-4i is the most frequently prescribed dual therapy.

DPP-4i is commonly used because it is associated with a relatively low risk of hypoglycemia and weight gain [6]. However, there are controversies regarding the HF risk associated with DPP-4i. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial infarction 53 (SAVOR-TIMI 53) trial demonstrated that saxagliptin was associated with increased rates of hospitalization for HF (HHF) [7]. The Examination of CV Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial [8] and the Trial Evaluating CV Outcomes with Sitagliptin trial revealed that alogliptin and sitagliptin did not increase the risk of HHF [9]. These discrepancies could have been caused by the different study designs and populations examined.

Our previous study revealed that MET+DPP-4i for T2D was associated with a lower CVD risk than that of MET+SU [10]. HF is a frequent and serious comorbidity of T2D that can be fatal. Considering this, we investigated the effect of DPP-4i and TZD as add-on therapies to MET in T2D patients on the risk of HHF using real-world data.

Materials and methods

This study was approved by the Institutional Review Board (IRB) of the Yonsei University Health System (IRB number 4-2015-1023). All datasets were anonymous and de-identified. As such, the need for informed consent was waived.

Data and study population

The National Health Insurance Service (NHIS) covers approximately 50 million people in Korea. In the NHIS claims database, diagnoses are coded using the International Classification of Disease version 10 (ICD-10). Insured individuals are required to undergo general health screenings every 2 years [11]. The health screening dataset includes information on height, weight, waist circumference, blood pressure, fasting glucose level, cholesterol level, health behaviors, and personal history of disease.

In Korea, MET is the most commonly prescribed drug in Korea [5]. MET can be prescribed as a first-line glucose-lowering treatment for T2D under health insurance coverage when the patient’s glycated hemoglobin is <53 mmol/mol (7.0%). Dual therapy can be started only if the glycemic target is not achieved despite MET monotherapy for at least 2–4 months. We selected T2D (ICD-10 codes E11–E14) and included patients treated with MET monotherapy for ≥90 days between January 2009 and December 2012 (n = 397,147) (Fig 1). The main
exposure was second-line glucose-lowering drugs added to MET for ≥90 days, and the initiation date of second-line glucose-lowering drugs after MET monotherapy for 90 days was defined as the index date. We selected individuals aged 30–90 years at the index date. Second-line glucose-lowering drugs of interest were limited to the three most common drugs: SU, DPP-4i, and TZD. We excluded individuals who continued MET monotherapy without second-line add-on. Then, people prescribed second-line glucose-lowering therapies, including insulin and drugs other than SU, DPP-4i, and TZD were excluded. We also excluded people with the event of CVD within 90 days after the index date. Three groups were followed until
the end of study, disregarding any regimen changes over time (intention-to-treat). Also, we used “on-treatment” analysis, which follow-up is censored at the time when the drug is changed [12]. The study outcome was the first occurrence of HHF (ICD-10: I50). The follow-up time was defined as the period between the index date and the study outcome. The end of the study period was 31 December 2015. Patients who died before the end of study date were censored. Glucose-lowering drugs were identified by the relevant Anatomic Therapeutic Chemical (ATC) code, a classification system for drugs created by the World Health Organization Collaborating Center for Drug Statistics Methodology. The following ATC codes were used in this study: A10BA02 for MET; A10BB and A10BD02 for SU; A10BH, A10BD07, A10BD08, A10BD10, A10BD11, A10BD13, and A10BD18 for DPP-4i; and A10BG, A10BD03, and A10BD05 for TZD.

**Covariates**

Comorbidities were adjusted using the Charlson Comorbidity Index and calculated by individual conditions, such as hypertension (ICD-10 codes I10–I15 and/or ATC codes C02–C03 and C07–C09), dyslipidemia (ICD-10 code E78 and/or ATC code C10), atrial fibrillation (ICD-10 code I48), chronic kidney disease (ICD-10 code N18), and microvascular complications of diabetes, including diabetic retinopathy (ICD-10 codes E10.3, E11.3, E12.3, E13.3, E14.3, and H36.0), diabetic neuropathy (ICD-10 codes E10.4, E11.4, E12.4, E13.4, E14.4, and G63.2), and diabetic nephropathy (ICD-10 codes E10.2, E11.2, E12.2, E13.2, E14.2, and N08.3). CVD included myocardial infarction (ICD-10 codes I21–I23), cerebrovascular diseases (ICD-10 codes E10.4, E11.4, E12.4, E13.4, E14.4, and G63.2), unstable angina (ICD-10 code I20.0), HF (ICD-10 code I50), and transient cerebral ischemic attack (ICD-10 code G45).

A subgroup analysis was performed to account for additional covariates, such as body mass index (BMI), waist circumference, systolic blood pressure, total cholesterol level, high-density lipoprotein (HDL) cholesterol level, low-density lipoprotein (LDL) cholesterol level, triglyceride level, fasting glucose level, serum creatinine level, smoking status (non-smoker, former smoker, or current smoker), and family history of stroke and heart disease. These variables were measured via health screening within 1 year before the index date. We used available data from patients who had undergone health screening (n = 35,297).

**Statistical analyses**

Baseline characteristics were compared between patients treated with the different second-line glucose-lowering drugs. Cox proportional hazard regression models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the incidence of HHF. We tested the proportional hazards assumption on the basis of Schoenfeld residuals [13]. The MET+SU regimen was used as a reference group for comparisons with the other second-line regimens. Potential confounders were sequentially adjusted in two statistical models, as follows: model 1 = sex and age; model 2 = sex, age, duration of MET therapy, hypertension, dyslipidemia, atrial fibrillation, chronic kidney disease, microvascular complications of diabetes (retinopathy, neuropathy, and nephropathy), previous history of CVD, Charlson Comorbidity Index, and calendar index year. All analyses were conducted using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA).

**Results**

**Risk of hospitalization for heart failure by claim data**

The patients were divided into the following three groups: MET+SU (n = 42,683), MET+DPP-4i (n = 50,310), and MET+TZD (n = 5,390). The mean index age of the study population was
58.3 ± 11.1 years, and 53.4% were men. Compared to MET+SU users, MET+DPP-4i users and MET+TZD users were younger, had a higher prevalence of microvascular complications such as diabetic retinopathy, neuropathy, and nephropathy, had a lower prevalence of hypertension, and had a higher prevalence of dyslipidemia (Table 1). Over 346,991 person-years of follow-up, 1,949 HHF events were observed. The sex and age-adjusted HR of experiencing an HHF event was 0.80 (95% CI 0.73–0.88) for MET+DPP-4i therapy compared to MET+SU therapy (reference). This lower HR risk remained statistically significant after additional adjustments. The risk of HHF in MET+TZD users (sex and age-adjusted HR 0.94, 95% CI 0.78–1.15) was lower than that in MET+SU users without statistical significance (Table 2). By using “on-treatment” analysis as mentioned in method, the use of MET+DPP-4i compared to MET+SU was associated with a 16% lower rate of development of heart failure consistent to the intention-to-treat that we used (S1 Table). Cumulative risk of HHF was significantly lower in MET+DPP-4i compared with MET+SU (S1 Fig).

Table 1. Baseline characteristics by type of second-line antidiabetic medication.

|                          | Total (n = 98,383) | MET+SU (n = 42,683) | MET+DPP4i (n = 50,310) | MET+TZD (n = 5,390) |
|--------------------------|--------------------|---------------------|------------------------|---------------------|
| **Men**                  | 52,520 (53.4)      | 22,581 (52.9)       | 26,946 (53.6)          | 2,993 (55.5)        |
| **Age, years**           | 58.3 ± 11.1        | 59.6 ± 11.3         | 57.2 ± 10.9            | 57.6 ± 11.1         |
| **Inclusion year**       |                    |                     |                        |                     |
| 2009                     | 49,960 (50.8)      | 21,827 (51.1)       | 25,030 (49.8)          | 3,103 (57.6)        |
| 2010                     | 26,278 (26.7)      | 11,025 (25.8)       | 13,953 (27.7)          | 1,300 (24.1)        |
| 2011                     | 13,271 (13.5)      | 5,679 (13.3)        | 7,000 (13.9)           | 592 (11.0)          |
| 2012                     | 8,874 (9.0)        | 4,152 (9.7)         | 4,327 (8.6)            | 395 (7.3)           |
| **Comedications**        |                    |                     |                        |                     |
| Statin therapy           | 58,357 (59.3)      | 22,681 (53.1)       | 32,229 (64.1)          | 3,447 (64.0)        |
| ACE inhibitors           | 5,334 (5.4)        | 2,683 (6.3)         | 2,362 (4.7)            | 289 (5.4)           |
| ARB                      | 54,986 (55.9)      | 23,978 (56.2)       | 28,017 (55.7)          | 2,991 (55.5)        |
| Loop diuretics           | 5,883 (6.0)        | 2,986 (7.0)         | 2,560 (5.1)            | 337 (6.3)           |
| Beta blockers            | 20,610 (20.9)      | 9,568 (22.4)        | 9,963 (19.8)           | 1,079 (20.0)        |
| Dihydropyridines         | 29,692 (30.2)      | 15,427 (36.1)       | 12,689 (25.2)          | 1,576 (29.2)        |
| Non-hydropyridines       | 3,173 (3.2)        | 1,343 (3.2)         | 1,676 (3.3)            | 154 (2.9)           |
| Low dose acetylic salicylic acid | 39,745 (40.4) | 18,001 (42.2)       | 19,659 (39.1)          | 2,085 (38.7)        |
| Warfarin                 | 1,268 (1.3)        | 573 (1.3)           | 643 (1.3)              | 52 (1.0)            |
| **Comorbidities**        |                    |                     |                        |                     |
| Hypertension             | 69,470 (70.6)      | 30,811 (72.2)       | 34,906 (69.4)          | 3,753 (69.6)        |
| Dyslipidemia             | 70,418 (71.6)      | 27,489 (64.4)       | 38,911 (77.3)          | 4,018 (74.6)        |
| Atrial fibrillation      | 1,780 (1.8)        | 724 (1.7)           | 991 (2.0)              | 102 (1.9)           |
| Chronic kidney disease   | 779 (0.8)          | 295 (0.7)           | 419 (0.8)              | 65 (1.2)            |
| Diabetic retinopathy     | 11,416 (11.6)      | 4,505 (10.6)        | 6,301 (12.5)           | 610 (11.3)          |
| Diabetic neuropathy      | 8,251 (8.4)        | 3,449 (8.1)         | 4,336 (8.6)            | 466 (8.7)           |
| Diabetic nephropathy     | 4,550 (4.6)        | 1,313 (3.1)         | 2,949 (5.9)            | 288 (5.3)           |
| Cardiovascular disease   | 16,184 (16.4)      | 7,227 (16.9)        | 8,065 (16.0)           | 892 (16.6)          |
| Charlson score, unit     | 2.9 ± 1.6          | 2.8 ± 1.6           | 2.9 ± 1.6              | 3.0 ± 1.6           |

Values are presented as the mean ± standard deviation or n (%). MET, metformin; SU, sulfonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, aldosterone receptor blocker.

https://doi.org/10.1371/journal.pone.0211959.t001
To assess whether a history of CVD affected the relationship between the types of add-on medication and the risk of HHF, we repeated the analysis separately for people with and those without a history of CVD (Table 3). Compared with use of MET+SU, the use of MET+DPP-4i was associated with an 18% lower rate of HHF in the group with a history of CVD (HR 0.82, 95% CI 0.70–0.96) and a 28% lower rate of HHF in the group without a history of CVD (HR 0.72; 95% CI 0.63–0.82). The risk of HHF in MET+TZD users compared to MET+SU was higher in group with CVD history, and lower in group without CVD history, without significance.

Subgroup analysis using national health screening data

The NHIS claims data included all physician-diagnosed disorders coded by ICD-10 but did not include objective data on exposure levels to CV risk factors. Therefore, we performed a subgroup analysis with available health screening data. In total, 35,297 people (35.9%) remained with available screening data and 498 per 100,000 person-years experienced HHF. Using MET+SU as a reference group, the HRs for HHF adjusted by age and sex were 0.74 (95% CI 0.61–0.89) for MET+DPP-4i and 1.11 (95% CI 0.77–1.59) for MET+TZD, respectively (Table 4). Moreover, the lowered HHF risks of the MET+DPP-4i group were also observed in comparison to the MET+SU group after adjusting for additional covariates. The baseline characteristics of patients treated with the different second-line drugs are shown in S2 Table.

### Table 2. Hazard ratios for the development of heart failure by type of second-line antidiabetic medication.

| Drugs    | Person-years | No. of cases | Event rate (per 100,000 PY) | Adjusted 1* | Adjusted 2† |
|----------|--------------|--------------|----------------------------|-------------|-------------|
|          |              |              |                            | HR (95% CI) | HR (95% CI) |
| MET+SU   | 171516       | 1129         | 658                        | 1.00        | 1.00        |
| MET+DPP-4i | 156163     | 710          | 455                        | 0.80 (0.73–0.88) | 0.76 (0.69–0.84) |
| MET+TZD  | 19312        | 110          | 570                        | 0.94 (0.78–1.15) | 0.96 (0.79–1.17) |

*Adjusted for sex and age.
†Adjusted for sex, age, the duration of metformin therapy, hypertension, dyslipidemia, atrial fibrillation, chronic kidney disease, microvascular complications of diabetes (retinopathy, neuropathy, or nephropathy), cardiovascular disease, the Charlson Comorbidity Index, and calendar index year.

### Table 3. Hazard ratios for the development of heart failure by type of second-line antidiabetic medication according to history of cardiovascular disease.

| Drugs    | CVD history (n = 16,184) | No CVD history (n = 82,199) |
|----------|--------------------------|-----------------------------|
|          | Person-years | No. of cases | Event rate (per 100,000 PY) | HR (95% CI) | Person-years | No. of cases | Event rate (per 100,000 PY) | HR (95% CI) |
| MET+SU   | 27,936       | 415          | 1,486                      | 1.00        | 143,580      | 714          | 497                       | 1.00        |
| MET+DPP-4i | 24,100      | 292          | 1,212                      | 0.82 (0.70–0.96) | 132,063      | 418          | 317                       | 0.72 (0.63–0.82) |
| MET+TZD  | 2,914        | 45           | 1,544                      | 1.10 (0.81–1.50) | 16,398       | 65           | 396                       | 0.88 (0.68–1.14) |

CVD, cardiovascular disease; MET, metformin; SU, sulfonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; HR, hazard ratio; CI, confidence interval; PY, person-year; no., number. Data are adjusted for sex, age, the duration of MET therapy, hypertension, dyslipidemia, atrial fibrillation, chronic kidney disease, microvascular complications of diabetes (retinopathy, neuropathy, or nephropathy), cardiovascular disease, the Charlson Comorbidity Index, and calendar index year.

https://doi.org/10.1371/journal.pone.0211959.0003
Discussion

The present study of nationwide real-world data demonstrated that people with T2D who were prescribed DPP-4i as a second-line drug alongside MET therapy had relatively lower risks of HHF than did those who were prescribed SU regardless of their CV history. These findings were directionally consistent across the subgroups that were available for further analysis using health screening data. Additionally, people who were prescribed TZD tended to have lower risks without statistical significance. This result could be explained by the fact that TZD was not prescribed to people at high risk of HHF because of doctors’ concerns about the high risks of HHF associated with TZD reported in previous studies [14, 15].

Many previous studies also reported the risk of HHF during monotherapy with glucose-lowering drugs [16–18]. Fu et al. revealed that individuals treated with DPP-4i had significantly lower risks of HHF among patients with no baseline CVD. The risk of HHF was lower in those treated with DPP-4i monotherapy than SU, pioglitazone, or insulin therapy alone [19]. When comparing the outcomes of second-line medication added to MET, MET+DPP-4i yielded a lower HR than MET+SU in terms of all-cause mortality, stroke, cancer, and the combined endpoint [10, 20, 21]. Recently, using Korean NHIS claim data, treatment with DPP-4i has been shown to be associated with a lower HF risk than treatment with SU [22]. Our previous study also demonstrated CVD risk reduction associated with MET+DPP-4i treatment for diabetes when compared to MET+SU [10].

As the NHIS health care utilization database did not include laboratory or anthropometric parameters, we employed strategies to maximize comparability between the three study groups. First, we limited our analysis to people treated using only one second-line therapy in addition to MET. Second, we excluded people who were not prescribed MET monotherapy before combination therapy or those who used MET monotherapy for <90 days. Third, we adjusted for the duration of MET monotherapy as a potential confounder. Finally, we performed a subgroup analysis using national health screening data from those who had undergone the relevant screening and further adjusted the results for objectively measured bioclinical variables. In subgroup analysis, our results confirmed that adding DPP-4i to MET reduced the incidence of HHF compared to that on using MET+SU. In our population, the proportion of people with chronic kidney disease and diabetic micro-vascular complications (retinopathy, neuropathy, and nephropathy) was relatively low, suggesting that these results could reflect the risk of HHF in the early stage of T2D.

This study has several limitations. First, HHF was defined by an ICD-10 code from the NHIS health care utilization data, not by clinical or laboratory tests. Thus, there is the

| Drugs     | Person-years | No. of cases | Event rate (per 100,000 PY) | Adjusted 1* | Adjusted 2† |
|-----------|--------------|--------------|-----------------------------|-------------|-------------|
| MET+SU    | 57,209       | 280          | 489                         | 1.00        | 1.00        |
| MET+DPP-4i| 59,428       | 185          | 311                         | 0.74 (0.61–0.89) | 0.65 (0.54–0.79) |
| MET+TZD   | 6,949        | 33           | 475                         | 1.11 (0.77–1.59) | 1.05 (0.73–1.51) |

MET, metformin; SU, sulfonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; HR, hazard ratio; CI, confidence interval; PY, person-year; no., number
*Adjusted for sex and age.
†Adjusted for sex, age, the duration of metformin therapy, body mass index, waist circumference, systolic blood pressure, total cholesterol level, high-density lipoprotein cholesterol level, low-density lipoprotein cholesterol level, triglyceride level, fasting glucose level, serum creatinine level, smoking status, family history of stroke and heart disease, history of cardiovascular disease, Charlson Comorbidity Index, and calendar index year.

https://doi.org/10.1371/journal.pone.0211959.t004
possibility of outcome misclassification. Second, the study had a relatively short follow-up duration. Further studies are needed to compare the long-term effects of second-line glucose-lowering drugs. Third, we did not examine safety profiles, such as diabetic ketoacidosis events or hypoglycemic events, during the follow-up period. Fourth, we did not compare the effects between the subclasses of DPP-4i. We also could not include new drugs such as sodium-glucose co-transporter-2 inhibitor, which was introduced in 2015, and glucagon-like peptide-1 receptor agonist, which was not covered by health insurance in Korea during the study period. Comparative studies of new emerging drugs that have recently started to be prescribed are expected in the near future. Fifth, in contrast to the SAVOR-TIMI 53 trial, in which DPP-4i was associated with higher risks of HHF, the protective effect of DPP-4i on HHF detected in this study could have resulted from the fact that we used SU as a reference for comparisons. Finally, we did not check glycated hemoglobin (HbA1c), reflecting the level of blood sugar controlled over the past 2 to 3 months, so we only adjusted for fasting glucose level.

Despite these limitations, the current study has several important strengths. The claims data related to ICD-10 codes and health screening data, which can reflect the biochemical and anthropometric status of patients, were combined to analyze the differences in the risks of HHF on using DPP-4i, TZD, and SU as add-on therapies to MET. We confirmed that DPP-4i added to MET reduced the risk of HHF despite the limitation of defining HHF by an ICD-10 code from NHIS claims data in the subgroup analysis. Smoking status and personal and family histories of CVD, which were determined via surveys during health screening, were also considered when analyzing the risk of HHF. This study was performed in a population of patients who started taking MET at diagnosis, which more closely reflects the common pattern of administration of oral glucose-lowering drugs under insurance coverage for the relatively early stages of T2D in Korea. It is worth analyzing the effect of add-on therapy patterns to MET using real-world data. Finally, we analyzed the risk of HHF people based on an underlying history of CVD.

Conclusions

An add-on therapy to MET is often required for people with T2D who fail to respond to MET monotherapy. When trying to achieve glycemic control targets, HHF, a risk associated with CVD, should be considered when choosing from the available second-line drugs. This study of nationwide real-world data comparing add-on glucose-lowering medications suggests that DPP-4i added to MET might lower the risks of HHF compared to SU, irrespective of the patient’s history of CVD. More investigative studies with longer follow-up durations assessing the drugs used in the present study or new and emerging drugs such as SGLT-2i or GLP-1 agonist are needed to better reflect real-world practice.

Supporting information

S1 Table. Hazard ratios for the development of heart failure by type of second-line antidiabetic medication in on-treatment analysis.

S2 Table. Baseline characteristics of second-line drugs in the subgroup with available health screening data. Data are reported as means ± standard deviations, medians [25th–75th percentiles], or numbers (percentages) unless otherwise stated. CVD, cardiovascular disease; MET, metformin; SU, sulfonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

(DOC)
S1 Fig. Cumulative risk of hospitalization of heart failure (HHF) events in Korean adults with type-2 diabetes from the Korean National Health Insurance database.

(TIF)

Acknowledgments
The authors thank Dae In Kim (Librarian, Yonsei University Medical Library) for his assistance in formatting the manuscript.

Author Contributions
Conceptualization: Su Jin Lee, Dae Jung Kim, Hyeon Chang Kim.
Data curation: Jung Hyun Lee.
Formal analysis: Kyoung Hwa Ha.
Funding acquisition: Dae Jung Kim, Hyeon Chang Kim.
Investigation: Su Jin Lee.
Methodology: Su Jin Lee, Kyoung Hwa Ha, Jung Hyun Lee, Hokyou Lee.
Project administration: Dae Jung Kim, Hyeon Chang Kim.
Supervision: Dae Jung Kim, Hyeon Chang Kim.
Validation: Kyoung Hwa Ha.
Writing – original draft: Su Jin Lee.
Writing – review & editing: Jung Hyun Lee, Hokyou Lee, Dae Jung Kim, Hyeon Chang Kim.

References
1. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. The lancet Diabetes & endocrinology. 2014; 2(10):843–51. Epub 2014/04/16. https://doi.org/10.1016/s2213-8587(14)70091-2 PMID: 24731868.
2. Packer M. Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. Diabetes Care. 2018; 41(1):11–3. https://doi.org/10.2337/dc17-0052 PMID: 29263193
3. American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018; 41(Suppl 1):S73–S85. Epub 2017/12/10. https://doi.org/10.2337/dc18-S008 PMID: 29222379.
4. Ko S-H, Han K, Lee Y-h, Noh J, Park C-Y, Kim D-J, et al. Past and Current Status of Adult Type 2 Diabetes Mellitus Management in Korea: A National Health Insurance Service Database Analysis. Diabetes Metab J. 2018; 42(2):93–100. https://doi.org/10.4093/dmj.2018.42.2.93 PMID: 29676539
5. Rhee SY, Kim HJ, Ko SH, Hur KY, Kim NH, Moon MK, et al. Monotherapy in patients with type 2 diabetes mellitus. The Korean journal of internal medicine. 2017; 32(6):959–66. Epub 2017/10/24. https://doi.org/10.3904/kjim.2017.312 PMID: 29057643; PubMed Central PMCID: PMCPMC666804.
6. Tellia SH, Rendell MS. DPP-4 inhibitors: focus on safety. Expert Opinion on Drug Safety. 2015; 14(1):127–40. https://doi.org/10.1517/14740338.2015.977863 PMID: 25486788.
7. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. Circulation. 2015; 132(15):e198. Epub 2015/10/16. https://doi.org/10.1161/CIRCULATIONAHA.115.019082 PMID: 26459088.
8. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet (London, England). 2015; 385(9982):2067–76. Epub 2015/03/13. https://doi.org/10.1016/S0140-6736(14)62225-x PMID: 25765690.
Secondary Analysis of a Randomized Clinical Trial. JAMA cardiology. 2016; 1(2):126–35. Epub 2016/07/22. https://doi.org/10.1001/jamacardio.2016.0103 PMID: 27437883.

10. Ha KH, Kim B, Choi H, Kim DJ, Kim HC. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data. Diabetic medicine: a journal of the British Diabetic Association. 2017; 34(9):1235–43. Epub 2017/05/20. https://doi.org/10.1111/dme.13384 PMID: 28523719.

11. Cheol Seong S, Kim Y-Y, Khang Y-H, Heon Park J, Kang H-J, Lee H, et al. Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. International Journal of Epidemiology. 2017; 46(3):799–800. https://doi.org/10.1093/ije/dyw253 PMID: 27794523.

12. Chêne G, Morlat P, Leport C, Hafner R, Dequae L, Charreau I, et al. Intention-to-Treat vs. On-Treatment Analyses of Clinical Trial Data: Experience from a Study of Pyrimethamine in the Primary Prophylaxis of Toxoplasmosis in HIV-Infected Patients. Controlled Clinical Trials. 1998; 19(3):233–48. https://doi.org/10.1016/S0197-2456(97)00145-1.

13. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81(3):515–26. https://doi.org/10.1093/biomet/81.3.515

14. Singh S, Loke YK, Furberg CD. Thiazolidinediones and Heart Failure. A teleo-analysis. 2007; 30(8):2148–53. https://doi.org/10.2337/dc07-0141 PMID: 17536074.

15. Komajda M, McMurray JJV, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European heart journal. 2010; 31(7):824–31. https://doi.org/10.1093/eurheartj/ehp604 PMID: 2118174.

16. Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, et al. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study. Diabetes Care. 2016; 39(5):726–34. Epub 2016/01/08. https://doi.org/10.2337/dc15-0764 PMID: 26740636.

17. Fadini GP, Avogaro A, Degl’Espositi L, Russo P, Saragoni S, Buda S, et al. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. European heart journal. 2015; 36(36):2454–62. Epub 2015/06/27. https://doi.org/10.1093/eurheartj/ehv301 PMID: 26112890.

18. Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, et al. Antidiabetic Drugs and Heart Failure Risk in Patients With Type 2 Diabetes in the U.K. Primary Care Setting. Diabetes Care. 2005; 28(1):20–6. https://doi.org/10.2337/diacare.28.1.20 PMID: 15616228.

19. Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, et al. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. Annals of internal medicine. 2016; 164(11):705–14. Epub 2016/04/26. https://doi.org/10.7326/M15-2568 PMID: 27110660; PubMed Central PMCID: PMC518978.

20. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(12):4605–12. Epub 2012/10/19. https://doi.org/10.1210/jc.2012-3034 PMID: 23076348.

21. Chang YC, Chuang LM, Lin JW, Chen ST, Lai MS, Chang CH. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. Diabetic medicine: a journal of the British Diabetic Association. 2015; 32(11):1460–9. Epub 2015/05/15. https://doi.org/10.1111/dme.12800 PMID: 25970814.

22. Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, et al. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study. Circulation Heart failure. 2017; 10(9). Epub 2017/09/14. https://doi.org/10.1161/circheartfailure.117.003957 PMID: 28899989.